Trials / Completed
CompletedNCT03666715
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
A Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 55 (actual)
- Sponsor
- Janssen-Cilag Farmaceutica Ltda. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of Paliperidone Palmitate 1-month formulation treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Antipsychotics (OAPs) | No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice. |
| DRUG | Paliperidone Palmitate 1-Month Formulation (PP1M) | No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice. |
Timeline
- Start date
- 2018-08-07
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
- First posted
- 2018-09-12
- Last updated
- 2025-04-27
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT03666715. Inclusion in this directory is not an endorsement.